Seock‐Ah Im

Also affiliated with Seoul National University Hospital

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I/II open‐label, dose escalation study”.

Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I/II open‐label, dose escalation study

International Journal of Cancer(2021)10.1002/ijc.33861

N/A

1.9DataRank · unranked

62 citations

Jean‐Yves Blay, Irene García, Johann S. De Bono, Christophe Le Tourneau, Víctor Moreno +25 more

Serial monitoring of genomic alterations in circulating tumor cells of ER‐positive/HER2‐negative advanced breast cancer: feasibility of precision oncology biomarker detection

Molecular Oncology(2021)10.1002/1878-0261.13150

N/A

0DataRank · unranked

21 citations

Emily M. Dolce, Elizabeth P. Darga, Kevin Hu, Chia‐Jen Liu, Jackie Pierce +27 more

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Annals of Oncology(2022)10.1016/j.annonc.2022.09.159

N/A

0DataRank · unranked

450 citations

Judy E. Garber, Richard D. Gelber, Greg Yothers, Manuel Taboada, L. Ross +93 more

OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

European Journal of Cancer(2023)10.1016/j.ejca.2023.01.031

N/A

0DataRank · unranked

113 citations

Seock‐Ah Im, Elżbieta Senkus, Binghe Xu, Susan M. Domchek, Norikazu Masuda +8 more

The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody–drug conjugate–resistant HER2-overexpressing breast cancer

Journal of Experimental & Clinical Cancer Research(2024)10.1186/s13046-024-03143-3

N/A

0DataRank · unranked

27 citations

Kumiko Kida, Jiwon Koh, Huey Liu, Ganiraju C. Manyam, Young Jin Gi +12 more